Endo International | Sustainability Performance
Develops and markets branded and generic pharmaceuticals and medical devices.
1920
United States
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
$10M - 25M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#12083
Overallⓘ#2804
in United Statesⓘ#283
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Endo International plc (post-2024 Endo Inc emergence from Chapter 11) — Irish-incorporated US-operating major specialty pharmaceutical (Para Pharmaceutical/Generic, Branded Pharmaceuticals incl Vasostrict, Adrenalin) — has faced sustained scrutiny over the historic August 2022 Endo Chapter 11 bankruptcy filing (USD 8+ billion debt restructuring) following sustained US opioid litigation customer compliance affecting Endo's institutional creditor governance complexity amid US opioid sector regulatory pressure (Opana ER opioid product 2017 FDA market withdrawal).
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
4-6
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.